Active Biotech AB (publ) (FRA:BTPC)

Germany flag Germany · Delayed Price · Currency is EUR
0.0036
-0.0001 (-2.70%)
At close: Jan 22, 2026
-40.00%
Market Cap10.41M -0.6%
Revenue (ttm)n/a
Net Income-3.48M
EPS-0.00
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume8,659
Open0.0036
Previous Close0.0037
Day's Range0.0036 - 0.0036
52-Week Range0.0016 - 0.0307
Betan/a
RSI48.62
Earnings DateFeb 12, 2026

About Active Biotech AB

Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as non-infectious uveitis; Tasquinimod, an orally active small molecule immunomodulator that blocks tumor-promoting signals in the bone marrow microenvir... [Read more]

Industry Pharmaceutical Preparations
Founded 1983
Employees 5
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol BTPC
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements

News

Active Biotech AB: Active Biotech's patent related to a pharmaceutical formulation of tasquinimod will be granted in the US

Lund, November 25, 2025, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent and Trademark Office (USPTO) has issued a notification that the company's patent application rela...

2 months ago - Finanz Nachrichten